1. Home
  2. BOW vs RGNX Comparison

BOW vs RGNX Comparison

Compare BOW & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$24.29

Market Cap

913.3M

Sector

Finance

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$14.92

Market Cap

759.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOW
RGNX
Founded
2020
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.3M
759.3M
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
BOW
RGNX
Price
$24.29
$14.92
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$35.00
$30.78
AVG Volume (30 Days)
187.9K
716.0K
Earning Date
02-24-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
44.06
N/A
EPS
1.55
N/A
Revenue
$519,241,000.00
$161,318,000.00
Revenue This Year
$16.05
$132.80
Revenue Next Year
$25.43
$45.32
P/E Ratio
$16.12
N/A
Revenue Growth
33.44
91.30
52 Week Low
$23.50
$5.04
52 Week High
$42.29
$15.84

Technical Indicators

Market Signals
Indicator
BOW
RGNX
Relative Strength Index (RSI) 30.47 58.17
Support Level $28.12 $14.55
Resistance Level $26.21 $15.84
Average True Range (ATR) 0.82 0.83
MACD -0.47 0.02
Stochastic Oscillator 1.49 69.36

Price Performance

Historical Comparison
BOW
RGNX

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: